Although we cannot exclude that other neuronal protection mechanisms exist, the results support the relevance of plasmalemma localized VDAC-1 as a target for optimizing neuroprotective approaches in clinical settings of transplantation and neurodegenerative diseases that are based on already available function-blocking monoclonal antibody. This evidence concerns the gene VDAC1 and neurodegenerative disease.